Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review

Author(s): Mohsen Sheykhhasan*.

Journal Name: Current Stem Cell Research & Therapy

Volume 14 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

[1]
Pawitan JA, Yang Z, Wu YN, Lee EH. Towards standardized stem cell therapy in type 2 diabetes mellitus: a systematic review. Curr Stem Cell Res Ther 2018; 13(6): 476-88.
[2]
Organization WH. Global report on diabetes. World Health Organization 2016.
[3]
Guthrie RM. Evolving therapeutic options for type 2 diabetes mellitus: An overview. J Postgrad Med 2012; 124(6): 82-9.
[4]
Choe C, Edelman S. New therapeutic options for treating type-2 diabetes: A review of insulin analogs and premixed insulin analogs. J Natl Med Assoc 2007; 99(4): 357.
[5]
Chaudhury A, Duvoor C, Dendi R, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol 2017; 8: 6.
[6]
Church TJ, Haines ST. Treatment approach to patients with severe insulin resistance. Clin Diabetes 2016; 34(2): 97-104.
[7]
El-Badawy A, El-Badri N. Clinical efficacy of stem cell therapy for diabetes mellitus: A meta-analysis. PLoS One 2016; 11(4): e0151938.
[8]
Kaplan W, Wirtz V, Mantel A, Béatrice P. Priority medicines for Europe and the World Update 2013 report. Methodology 2013; 2(7)
[9]
Baynes H. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab 2015; 6(5): 1-9.
[10]
Wang L, Zhao S, Mao H, Zhou L, Wang Z, Wang H. Autologous bone marrow stem cell transplantation for the treatment of type 2 diabetes mellitus. Chin Med J 2011; 124(22): 3622-8.
[11]
Estrada EJ, Valacchi F, Nicora E, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. Cell Transplant 2008; 17(12): 1295-304.
[12]
Tong Q, Duan L, Xu Z, et al. Improved insulin secretion following intrapancreatic UCB transplantation in patients with T2DM. J Clin Endocrinol Metab 2013; 98(9): E1501-4.
[13]
Hu J, Li C, Wang L, et al. Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. Endocrine J 2012; 59(11): 1031-9.
[14]
Bhansali A, Asokumar P, Walia R, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant 2014; 23(9): 1075-85.
[15]
Bhansali A, Upreti V, Khandelwal N, et al. Efficacy of autologous bone marrow–derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev 2009; 18(10): 1407-16.
[16]
Le PT-B, Van Pham P, Vu NB, Dang LT-T, Phan NK. Expanded autologous adipose derived stem cell transplantation for type 2 diabetes mellitus. Biomed Res Ther 2016; 3(12): 1034-44.
[17]
Liu Y, Guo L, Xu J. Amniotic stem cell transplantation therapy for type 2 diabetes: 3 years’ follow-up report. Eur Rev Med Pharmacol Sci 2016; 20(18): 3877-85.
[18]
Bahk JY, Jung JH, Han H, Min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. Exp Clin Transplant 2010; 8(2): 150-60.
[19]
Li X-Y, Zheng Z-H, Li X-Y, et al. Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: response and correction of immunological anomalies. Curr Pharm Des 2013; 19(27): 4893-9.
[20]
Guan LX, Guan H, Li HB, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med 2015; 9(5): 1623-30.
[21]
Liu X, Zheng P, Wang X, et al. A preliminary evaluation of efficacy and safety of Wharton’s jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cell Res Ther 2014; 5(2): 57.
[22]
Hu J, Wang Y, Gong H, et al. Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med 2016; 12(3): 1857-66.
[23]
Aagaard T, Lund H, Juhl C. Optimizing literature search in systematic reviews–are medline, embase and central enough for identifying effect studies within the area of musculoskeletal disorders? BMC Med Res Methodol 2016; 16(1): 161.
[24]
Toyserkani NM, Jørgensen MG, Tabatabaeifar S, Jensen CH, Sheikh SP, Sørensen JA. Concise review: a safety assessment of adipose‐derived cell therapy in clinical trials: a systematic review of reported adverse events. Stem Cells Transl Med 2017; 6(9): 1786-94.
[25]
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015; 4(1): 1.
[26]
Welch V, Petticrew M, Petkovic J, et al. Extending the PRISMA statement to equity-focused systematic reviews (PRISMA-E 2012): Explanation and elaboration. Int J Equity Health 2015; 14(1): 92.
[27]
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162(11): 777-84.
[28]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6(7): e1000100.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 14
ISSUE: 1
Year: 2019
Page: [75 - 76]
Pages: 2
DOI: 10.2174/1574888X1401181217125608

Article Metrics

PDF: 22
HTML: 8